Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A generates $5mm for Arcturus Therapeutics

Executive Summary

Arcturus Therapeutics Inc. (RNAi-based treatments for rare orphan respiratory diseases) raised $5mm through its Series A venture round. Several investors from the US, Canada, and Japan led, with about 90% of the June 2013 seed round backers returning. The company will use the money to nominate its first clinical drug candidate next year and expand its team. Since the $1.3mm seed round, the start-up has acquired from Marina Biotech intellectual property related to an unlocked nucleobase analog platform--a gene silencing technology used to improve RNAi therapeutics while retaining their potency.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies